S

Sanofi

Global pharma company; vaccines and R&D

Global HCP Marketing Lead - Duvakitug, IBD

Full-TimePosted on 10/20/2026Deadline 11/30/26
$178.5k - $257.8k
Expert
Bachelor's, MBA, PharmD, PhD
Cambridge, MA, USA
In Person
Growth & MarketingProduct Marketing

About the job

Requirements
  • A bachelor's degree in Life Sciences, Marketing, Business, or a related field is required.
  • At least 8 years of progressive pharmaceutical or biotechnology marketing experience, including healthcare professional marketing in specialty care.
  • Experience leading prelaunch and launch marketing for innovative therapies, including building marketing capabilities from the ground up.
  • Strong understanding of omnichannel marketing and digital healthcare professional engagement, with experience applying artificial intelligence technologies in pharmaceutical marketing.
  • Experience planning and facilitating advisory boards and strategic steering committees, and engaging key opinion leaders in a commercial context.
  • Agency management skills, including briefing, budget oversight, and performance management.
  • Knowledge of pharmaceutical regulatory and promotional review processes.
  • Ability to build strategic marketing plans and translate them into actionable, measurable campaigns.
  • Experience navigating complex specialty-care treatment landscapes.
  • Experience developing and executing disease awareness campaigns.
  • Global marketing experience across diverse markets and cultures, including the United States and Japan.
Responsibilities
  • Own the global healthcare professional marketing strategy for duvakitug in inflammatory bowel disease across prelaunch and launch, grounded in treatment-landscape, competitive, and customer insights.
  • Align cross-functional partners, including Medical Affairs, Market Access, Patient Advocacy, and Market Research, and key markets, notably the United States and Japan, on integrated, locally adapted execution.
  • Act as the thought leader on inflammatory bowel disease healthcare professional marketing for senior leadership.
  • Build and refine healthcare professional segmentation based on prescribing behavior, specialty, patient mix, and engagement preferences to guide targeting and resource allocation.
  • Translate segmentation into actionable omnichannel campaign plans and adjust them as the healthcare professional landscape evolves.
  • Design disease-state awareness campaigns and educational content to address healthcare professional knowledge gaps in inflammatory bowel disease diagnosis and management.
  • Lead the commercial key opinion leader engagement strategy, including identification, mapping, and cultivation, and partner with medical societies and patient advocacy to extend reach.
  • Plan and facilitate Advisory Boards and Strategic Steering Committees, and synthesize input into strategic recommendations.
  • Build lasting, trust-based key opinion leader relationships that support brand advocacy.
  • Develop evidence-based messaging and integrated omnichannel campaigns across digital, in-person, and hybrid channels for gastroenterologists, inflammatory bowel disease specialists, and other prescribers.
  • Oversee promotional and non-promotional materials, ensuring regulatory, legal, and medical compliance.
  • Lead the Agency of Record relationship end to end, including briefs, budget, performance evaluation, and fostering an agile, high-performing partnership.
  • Design seamless, personalized omnichannel healthcare professional experiences, applying artificial intelligence and analytics to targeting, personalization, and channel optimization.
  • Pilot emerging digital tools, including artificial intelligence, predictive analytics, and virtual platforms, for the duvakitug healthcare professional program.
  • Partner with Market Research and Competitive Intelligence to build a continuous insights framework that informs strategy, messaging, and campaigns.
  • Define key performance indicators and measurement frameworks to track campaign, engagement, and brand performance, and report insights to senior leadership.
  • Manage healthcare professional marketing budgets with rigor and accountability.
  • Serve as marketing liaison to Medical Affairs for scientific accuracy, Market Access for value messaging, and Patient Advocacy for patient-voice integration.
  • Partner with Teva counterparts to ensure alignment and consistent execution across Sanofi and Teva markets.
Desired Qualifications
  • Advanced degree such as an MBA, PharmD, or PhD.
  • Healthcare professional marketing experience in gastroenterology, immunology, or related therapeutic areas.
  • Background in gastroenterology, inflammatory bowel disease, or related inflammatory/autoimmune and biologics markets, with familiarity with the inflammatory bowel disease treatment landscape, including standard of care and emerging therapies.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...